Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health’s analysts said
European markets higher in shortened session ahead of Christmas; Novo Nordisk resumes recovery
European markets were trading higher on Tuesday, in a shortened trading session for Christmas Eve. The pan-European Stoxx 600 was up by around 0.3% during morning deals, with all sectors in positive territory.
What Analysts Are Saying About Novo Nordisk Stock
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00, and a low estimate of $105.00. A 8.65% drop is evident in the current average compared to the previous average price target of $159.00.
Why Novo Nordisk’s Stock Plunge Rattled Markets Today
Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowes
Novo Nordisk upgraded to Outperform from Market Perform at Handelsbanken
Handelsbanken upgraded Novo Nordisk (NVO) to Outperform from Market Perform with a DKK 1,000 price target Don't Miss Our Christmas
Novo Nordisk Shares Rebound After Friday’s $90B Wipeout: Retail, Analysts See Opportunity
Novo Nordisk shares on the NYSE rose over 5% in premarket trading Monday, reversing some losses from Friday’s plunge that marked their worst single-day drop in 22 years. The stock’s sharp decline, which erased $90 billion in market value,
Novo Nordisk shares rebound 8%: can European markets sustain the rally?
Novo Nordisk shares staged a dramatic rebound on Monday, recovering 8% after a steep 20% plunge on Friday. The recovery was sparked by investor reassessment of the company’s potential following disappointing trial results for its CagriSema weight-loss drug.
Novo Nordisk shares plunge on the back of disappointing trial results
Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday. View on euronews
Will Novo Nordisk (NVO) Stock Recover To $145 Levels?
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results
Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...
Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...